Halozyme Therapeutics HALO Operating lease right-of-use assets amortization expense
Operating lease right-of-use assets amortization expense at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's operating lease right-of-use assets amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's operating lease right-of-use assets amortization expense?
- Halozyme Therapeutics (HALO) reported operating lease right-of-use assets amortization expense of $2.6M in Q1 2026.
- How has Halozyme Therapeutics's operating lease right-of-use assets amortization expense changed year-over-year?
- Halozyme Therapeutics's operating lease right-of-use assets amortization expense increased by 73.3% year-over-year, from $1.5M to $2.6M.